Return to homepagePandemic Pact

Queensland

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:1000 publications

Grant number: N/A

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2020

  • Known Financial Commitments (USD)

    $4,500,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Principal Investigator

    Keith Chappel

  • Research Location

    Australia

  • Lead Research Institution

    University of Queensland

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Full length S-protein Molecular clamp (pre-fusion viral insertion proteins are stabilised using a sequence from HIV. This is applicable to type I and III glycoproteins). Phase I safety and immunogenicity

Publicationslinked via Europe PMC

Last Updated:5 days ago

View all publications at Europe PMC

Matrix degradation enhances stress relaxation, regulating cell adhesion and spreading.

Alcohol industry involvement in the delayed South Africa Draft Liquor Amendment Bill 2016: a case study based on freedom of information requests.

Pupil Wizard: an app to enhance knowledge of pupillary abnormalities.

Streptococcus pneumoniae serotype 33H: a novel serotype with frameshift mutations in the acetyltransferase gene wciG.

An enhanced national-scale urban tree canopy cover dataset for the United States.

Impact of postpartum physical activity on maternal anthropometrics: a systematic review and meta-analysis.

Redox dye-mediated fluorescence energy transfer of carbon nanotube-based nanosensors.

Disease burden by <i>ALPL</i> variant number in patients with non-life-threatening hypophosphatasia in the Global HPP Registry.

Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes.